Can I Take St. John's Wort with Prometrium? Interaction Risks Explained

Prometrium is the brand name for oral micronized progesterone, FDA-approved for endometrial protection in women taking estrogen therapy and for secondary amenorrhea. St. John's Wort (Hypericum perforatum) is an herbal supplement sold over the counter, most often used for mild depressive symptoms. It is not FDA-approved as a drug in the United States and is regulated as a dietary supplement, meaning its potency and hyperforin content are not standardized the way a prescription drug is.

The general recommendation from clinical pharmacology sources is to avoid combining the two, or to do so only with clinician oversight. St. John's Wort is a well-documented inducer of the CYP3A4 liver enzyme, and CYP3A4 is one of the enzymes responsible for breaking down oral micronized progesterone. Inducing that enzyme is expected, on pharmacological grounds, to lower circulating progesterone levels. Whether that translates into a specific percentage reduction, or into measurable loss of endometrial protection, has not been directly studied in women taking Prometrium and St. John's Wort together. That is a genuine evidence gap, not a reason for reassurance.

The direct answer, with its boundary

St. John's Wort is a known CYP3A4 inducer, and oral micronized progesterone is partly metabolized by CYP3A4, so combining them is pharmacologically expected to reduce progesterone exposure. This mechanism is established for other CYP3A4 substrates (drugs such as cyclosporine, midazolam, and oral contraceptives have shown clinically meaningful reductions in blood levels when co-administered with St. John's Wort). No dedicated pharmacokinetic study of St. John's Wort with micronized progesterone has been identified in this review, so the exact magnitude of the interaction for Prometrium specifically is inferred, not directly measured. Clinicians generally treat this as a class-level interaction warranting avoidance or monitoring rather than a documented, quantified one.

Why the mechanism is plausible: CYP3A4 induction

St. John's Wort contains hyperforin, a compound that activates the pregnane X receptor (PXR) in the liver and intestinal wall. Activated PXR increases transcription of the CYP3A4 gene, which raises the amount of CYP3A4 enzyme available to metabolize drugs that pass through it. A past FDA public health advisory on St. John's Wort warned that the herb appears to be an inducer of an important metabolic pathway, cytochrome P450 3A4, and may reduce the effectiveness of many co-administered drugs, and specifically flagged oral contraceptives, a hormonal drug class metabolized through the same pathway.

Oral micronized progesterone already undergoes substantial first-pass metabolism, meaning a large share of an oral dose is broken down before it reaches systemic circulation. Adding an enzyme inducer on top of that first-pass effect is expected to reduce the fraction of active drug that reaches the bloodstream further. This reasoning is grounded in general CYP3A4 pharmacology and in the Prometrium prescribing information, which lists CYP3A4 inducers as a category of concern and instructs prescribers to watch for reduced efficacy when such agents are co-administered.

Why dose spacing does not fix this: interactions caused by competition for absorption in the gut (calcium with levothyroxine, for example) can sometimes be managed by taking the two products hours apart. CYP3A4 induction is different. Once the enzyme is upregulated, it stays elevated around the clock. Spacing Prometrium and St. John's Wort doses apart during the day would not be expected to reduce this interaction.

Evidence-status interaction assessment

What to watch for if you are taking both

Because the interaction is plausible but not quantified for this specific pair, the practical approach is to watch for clinical signs that progesterone effect may be inadequate rather than relying on a fixed timeline:

• New or returning breakthrough bleeding or spotting in a woman previously stable on combined HRT
• Return of hot flashes, night sweats, or mood symptoms that had been controlled
• Any of the above appearing after starting or increasing a St. John's Wort product

Unexpected vaginal bleeding in a postmenopausal woman on hormone therapy should always be evaluated by a clinician to rule out endometrial pathology, independent of supplement use. This is a standard gynecologic safety principle, not something specific to the St. John's Wort interaction.

If you are already taking both

The general, non-individualized guidance from a pharmacology standpoint is: do not stop Prometrium on your own, and talk to your prescriber promptly about the St. John's Wort. Stopping progesterone abruptly while continuing estrogen removes endometrial protection. Stopping St. John's Wort is usually the more conservative move, but the decision, and any need for dose adjustment or lab monitoring, belongs to the prescriber who knows the full regimen.

A clinician may consider checking a serum progesterone level to compare against a prior baseline if there is a reason to suspect reduced drug effect, though this is a judgment call made case by case rather than a routine, universally recommended test.

Alternatives for mood support during HRT

Several options for menopausal mood or vasomotor symptoms do not rely on CYP3A4 induction:

• Low-dose paroxetine (7.5 mg, brand name Brisdelle) is FDA-approved specifically for vasomotor symptoms associated with menopause, as a non-hormonal option.
• Other SSRIs and SNRIs are used off-label for menopausal mood and vasomotor symptoms; whether a particular agent is appropriate, and at what dose, depends on the individual's full medication list and history and should be decided with a prescriber.
• Cognitive behavioral therapy is a non-pharmacologic option with no pharmacokinetic interaction risk with Prometrium.
• Supplements such as magnesium, omega-3 fatty acids, or L-theanine are sometimes used for mild mood support and are not established CYP3A4 inducers, but their evidence for treating clinically significant depression is considerably weaker than for SSRIs or CBT, and none of this substitutes for a clinician's evaluation of significant mood symptoms.

What is not established

This page cannot confirm, from the sources reviewed, an exact percentage reduction in Prometrium blood levels caused by St. John's Wort, an exact number of days to onset or recovery of the interaction specific to progesterone, or a quantified change in endometrial hyperplasia or bleeding risk from this specific combination. Numbers repeated across consumer health sites for this pairing often trace back to interaction database severity ratings and analogy with other CYP3A4 substrates rather than to a dedicated clinical trial of St. John's Wort with micronized progesterone. Readers and clinicians should treat specific percentages for this exact combination as unverified until checked against a primary pharmacokinetic study or a current drug interaction database such as Lexicomp or the Natural Medicines database.

Bottom line

St. John's Wort and Prometrium share a plausible, mechanism-based interaction through CYP3A4 induction, consistent with FDA labeling language for both St. John's Wort generally and for CYP3A4 inducers in the Prometrium label. The size of that effect for progesterone specifically has not been directly measured in the sources available here. The reasonable approach is to avoid combining them without medical supervision, watch for breakthrough bleeding or return of menopausal symptoms, and involve a prescriber before starting, stopping, or adjusting either product.